文献速递血脂与心血管预防

脂蛋白分离治疗家族性高胆固醇血症的单中心研究

[Lipoprotein apheresis in patients with familial hypercholesterolemia: a single center research].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2022-01-01

该回顾性横断面研究纳入115例接受强化降脂但LDL-C未达标的家族性高胆固醇血症患者,采用双重滤过血浆置换进行脂蛋白分离治疗。治疗后LDL-C和Lp(a)分别降低64.2%和59.8%,免疫球蛋白变化在可接受范围,不良反应轻微,提示该治疗有效且安全。

要点

  • DFPP法脂蛋白分离可显著降低FH患者LDL-C和Lp(a)水平。
  • 治疗后IgG和IgA维持正常,IgM低于正常但不良反应轻微。
  • 对强化降脂未达标且Lp(a)升高的FH患者,LA是有效安全选择。

核心结论

  • 对于强化降脂后LDL-C不达标的FH患者,尤其是伴Lp(a)升高者,DFPP法LA可进一步大幅降低LDL-C和Lp(a),高效且安全。

研究设计与样本

  • 回顾性横断面研究,连续纳入2015年2月至2019年11月阜外医院接受LA治疗的FH患者115例。
  • 所有患者均在强化降脂药物治疗基础上采用双重滤过血浆置换法进行LA治疗。

主要发现

  • LA治疗前LDL-C为(5.20±2.94)mmol/L,治疗后即刻降至(1.83±1.08)mmol/L,降幅64.2%。
  • LA治疗前Lp(a)为428.70(177.00,829.50)mg/L,治疗后即刻降至148.90(75.90,317.00)mg/L,降幅59.8%,P<0.001。
  • LA治疗后1天IgG和IgA维持正常水平,降幅分别为15.1%和25.0%,IgM低于正常水平,降幅58.7%,P均<0.001。
  • 6例(5.2%)患者出现恶心、低血压、气短、心悸等轻微不良反应,经对症处理后缓解。

临床怎么用

  • 对最大耐受剂量降脂药物后LDL-C仍不达标的FH患者,可考虑DFPP法脂蛋白分离治疗。
  • 伴Lp(a)升高的FH患者可能从脂蛋白分离治疗中更多获益。
  • 治疗期间需监测免疫球蛋白水平及恶心、低血压等不良反应。

局限性

  • 本研究为回顾性横断面研究,未设对照组。
  • 单中心研究,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: We evaluated the safety and efficacy of lipoprotein apheresis (LA) in patients with familial hypercholesterolemia (FH) who can't reach low-density lipoprotein cholesterol(LDL-C) target goals with the maximal tolerated dose of lipid-lowering agents. Methods: This was a retrospective cross-sectional study. Between February 2015 and November 2019, patients with FH who were admitted in Fuwai hospital and treated with LA were consecutively enrolled. Based on intensive lipid-lowering agents, these patients received LA by double filtration plasma pheresis (DFPP) method. The changes of lipid levels such as LDL-C and lipoprotein(a)[Lp(a)] were compared before and after LA treatment, and the changes of immunoglobulin (Ig) concentration and LA-related adverse effects were also discussed. Results: A total of 115 patients with FH were enrolled in this study, of which 8 cases were homozygous FH and 107 cases were heterozygous FH. The age was (43.9±12.2) years and there were 75 (65.2%) males, and 108 (93.8%) with coronary artery disease. For pre-and immediately after LA treatment, the LDL-C was (5.20±2.94) mmol/L vs. (1.83±1.08) mmol/L, Lp(a) concentration was 428.70(177.00, 829.50)mg/L vs. 148.90(75.90, 317.00) mg/L (P<0.001), with a decrease of 64.2% and 59.8% respectively. The levels of IgG and IgA measured 1 day after LA treatment were both in the normal range and IgM concentration was below the reference value, the reductions of which were 15.1%, 25.0% and 58.7% respectively (P<0.001). Six patients had mild symptoms of nausea, hypotension dyspnea and palpitation, the symptoms were relieved by symptomatic treatment. Conclusion: For patients with FH who do not achieve LDL-C target goal with the maximal tolerated lipid-lowering agents, especially those with elevated Lp(a) levels, LA, which can significantly further reduce LDL-C and Lp(a) levels, is an effective and safe option. 目的: 探讨对于接受强化降脂药物治疗后低密度脂蛋白胆固醇(LDL-C)不能达标的家族性高胆固醇血症(FH)患者,采用脂蛋白分离即血脂净化(LA)治疗的有效性与安全性。 方法: 本研究为回顾性、横断面研究。连续选取2015年2月至2019年11月于中国医学科学院阜外医院进行LA治疗的FH患者,所有患者均在强化降脂药物治疗的基础上,采用双重滤过血浆置换(DFPP)法进行LA治疗。收集FH患者的年龄、性别、FH类型等基本临床信息,分析LA治疗前后LDL-C、脂蛋白a[Lp(a)]水平变化及其降幅,同时分析免疫球蛋白(Ig)变化以及LA治疗相关不良反应情况。 结果: 共计纳入115例FH患者,其中杂合型FH患者107例(93.0%)、纯合型8例(7.0%);年龄(43.9±12.2)岁,男性75例(65.2%),合并冠心病108例(93.8%)。LA治疗前LDL-C和Lp(a)水平分别为(5.20±2.94)mmol/L和[428.70(177.00,829.50)]mg/L,LA治疗后即刻LDL-C和Lp(a)水平均显著降低,分别降至(1.83±1.08)mmol/L和148.90(75.90,317.00)mg/L(P均<0.001),降幅分别达64.2%和59.8%。LA治疗后1 d IgG、IgA均可维持于正常水平(降幅分别为15.1%、25.0%,P均<0.001),IgM低于正常水平(降幅58.7%,P<0.001)。6例(5.2%)患者出现LA治疗相关不良反应,包括恶心、低血压、气短、心悸等,程度均轻微,经对症处理后症状缓解。 结论: 对于接受强化降脂药物治疗后LDL-C不达标的FH患者,尤其是伴Lp(a)升高者,DFPP法LA治疗可进一步大幅度降低LDL-C和Lp(a),是一种高效且安全的降脂治疗措施。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhao L, Gao Y, Liu G, et al. [Lipoprotein apheresis in patients with familial hypercholesterolemia: a single center research]. Zhonghua Xin Xue Guan Bing Za Zhi. 2022. PMID: 35705468. doi:10.3760/cma.j.cn112148-20210715-00591

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。